Wallace Adam N, Greenwood Taylor J, Jennings Jack W
Siteman Cancer Center, Mallinckrodt Institute of Radiology, Washington University School of Medicine, 510 South Kingshighway, St. Louis, MO, 63110, USA,
J Neurooncol. 2015 Aug;124(1):111-8. doi: 10.1007/s11060-015-1813-2. Epub 2015 May 29.
Radiofrequency ablation (RFA) and vertebral augmentation is an emerging combination therapy for painful osseous metastases that cannot be or are incompletely palliated with radiation therapy. Herein, we report our experience performing RFA and vertebral augmentation of spinal metastases for pain palliation. Institutional review board approval was obtained to retrospectively review our tumor ablation database for all patients who underwent RFA of osseous metastases between April 2012 and July 2014. Patient demographics, lesion characteristics, concurrent palliative therapies, and complications were recorded. Pre- and post-procedure mean worst pain scores 1 and 4 weeks after treatment were measured using the Numeric Rating Scale (10-point scale) and compared. During the study period, 72 RFA treatments of 110 spinal metastases were performed. Eighty one percent (89/110) of metastases involved the posterior vertebral body and 45 % (49/110) involved the pedicles. Vertebral augmentation was performed after 95 % (105/110) of ablations. Mean and median pre-procedure pain scores were 8.0 ± 1.9 and 8.0, respectively. Patients reported clinically significant decreased pain scores at both 1-week (mean, 3.9 ± 3.0; median, 3.25; P < 0.0001) and 4-week (mean, 2.9 ± 3.0; median, 2.75; P < 0.0001) follow-up. No major complications occurred related to RFA and there were no instances of symptomatic cement extravasation. Combination RFA and vertebral augmentation is a safe and effective therapy for palliation of painful spinal metastases, including tumor involving the posterior vertebral body and/or pedicles.
射频消融(RFA)与椎体强化术是一种针对无法通过放射治疗或放射治疗不完全缓解的疼痛性骨转移瘤的新兴联合治疗方法。在此,我们报告我们进行RFA及椎体强化术治疗脊柱转移瘤以缓解疼痛的经验。我们获得了机构审查委员会的批准,以回顾性分析2012年4月至2014年7月期间所有接受骨转移瘤RFA治疗的患者的肿瘤消融数据库。记录患者的人口统计学资料、病变特征、同期姑息治疗及并发症情况。使用数字评分量表(10分制)测量治疗后1周和4周的术前及术后平均最严重疼痛评分并进行比较。在研究期间,对110处脊柱转移瘤进行了72次RFA治疗。81%(89/110)的转移瘤累及椎体后部,45%(49/110)累及椎弓根。95%(105/110)的消融术后进行了椎体强化术。术前平均疼痛评分为8.0±1.9,中位数为8.0。患者报告在1周(平均,3.9±3.0;中位数,3.25;P<0.0001)和4周(平均,2.9±3.0;中位数,2.75;P<0.0001)随访时疼痛评分均有临床显著下降。未发生与RFA相关的重大并发症,也没有出现有症状的骨水泥渗漏情况。RFA与椎体强化术联合是一种安全有效的治疗方法,可缓解疼痛性脊柱转移瘤,包括累及椎体后部和/或椎弓根的肿瘤。